Mark Engel | CEO
Precisio Biotix

Day 1 - World Antimicrobial Resistance Congress & Disease Prevention Control Summit 2024 @ 12:00

Panel: Navigating the landscape - Strategies for early-stage developmental funding

The panel will address current strategies for early-stage funding chosen by the different panelists and give examples of successful company founding and funding. It will also address gaps and issues with the current funding landscape and within and between the supporting partners, and finally on novel business strategies chosen by the panelists to cope with those gaps. The addressed audience are start-ups, scientists and business developers in the AMR field and those planning to build a start-up, organizations supporting start-ups and everyone interested in early-stage development in the field of AMR.

Sponsored by LifeArc

Moderator: Peter Seiler, Management Team, Support of Ventures, INCATE

×

Peter Seiler / Panel: Navigating the landscape - Strategies for early-stage developmental funding

Peter Seiler, Management Team, Support of Ventures,
INCATE

Peter is an infection immunologist by training with a PhD from ETH Zürich. With over 25 years of experience in research and development of vaccines and small molecules against bacterial and mycobacterial pathogens, he has worked with large pharma and small to mid-sized biotech in Switzerland and...

CloseMore

Clive Mason, Programme Director, AMR, LifeArc

×

Clive Mason / Panel: Navigating the landscape - Strategies for early-stage developmental funding

Clive Mason, Programme Director, AMR,
LifeArc

Dr Clive Mason joined LifeArc in August 2023 to take on the role of Programme Director, AMR in the Global Health Team. Clive is also the LifeArc lead within the recently announced AMR-focused initiative called ‘PACE’ (Pathways to Antimicrobial Clinical Efficacy, https://paceamr.org.uk/ ). PACE was...

CloseMore

Alex Moreland, Cofounder & CEO, Xiretsa

×

Alex Moreland / Panel: Navigating the landscape - Strategies for early-stage developmental funding

Alex Moreland, Cofounder & CEO,
Xiretsa

Alex Moreland is co-founder and CEO of Xiretsa, a spinout from UC Santa Barbara which is developing selective membrane-remodeling antibiotics for critical AMR threats. Alex received his B.S. (UCSB, biology & chemistry) in 2012 and his Ph.D. (UCSB, chemistry) in 2019 under the guidance of...

CloseMore

Mark Engel, CEO, Precisio Biotix

Doug Witt, CEO, Unison Medicines

×

Doug Witt / Panel: Navigating the landscape - Strategies for early-stage developmental funding

Doug Witt, CEO,
Unison Medicines

Doug Witt is the CEO and cofounder of Unison Medicines, a discovery-stage pharmaceutical company focused on solving the Anti-Microbial Resistance crisis.  Unison discovers novel small molecules which block bacterial DNA damage repair and associated stress responses.  Previously Doug worked at...

CloseMore